

Imaginatik plc ("Imaginatik" or the "Company")

Pfizer Strategic Investment – Update

28 February 2008

The Company announced on 21 February 2008 that Pfizer Inc. ("Pfizer") had agreed to subscribe for up to 12,953,368 new ordinary shares ("Subscription Shares").

The subscription price for a Subscription Share ("Subscription Price") and number of Subscription Shares to be issued is based upon a 5% premium to the average closing offer price of an ordinary share in Imaginatik over the five dealing days following that announcement, being 21 February to 27 February 2008. This Subscription Price has now been calculated as 6.22209 pence per Subscription Share and Pfizer has subscribed for a total of 8,035,885 Subscription Shares representing 6.45 per cent. of the enlarged share capital.

Completion is conditional on admission to trading on AIM of the Subscription Shares occurring on or by 13 March 2008 ("Admission"). Application for Admission has been made today and is expected to occur on 6 March 2008.

Each Subscription Share will be issued credited as fully paid and free from all liens, equities, charges, encumbrances and other interests and will upon their issue rank in full for all dividends and distributions thereafter declared, made or paid after Admission and shall otherwise rank pari passu in all respects with, and carry the same voting and dividend rights as, the existing ordinary shares.

Pfizer has also agreed not to dispose of its interest in the Subscription Shares for a period of twelve months following Admission and for a subsequent period of twelve months not to dispose of such interests other than through W.H. Ireland Limited or the Company's broker at the time, without in each case the consent of the Company, and save in each case in certain limited circumstances.

Following the Subscription, the Company will have 124,637,111 ordinary shares in issue.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company.

For further information please contact:

Imaginatik plc
Mark Turrell, CEO / Shawn Taylor, CFO

Tel: +44 (0)20 7917 2975

W.H. Ireland
Tim Cofman/Katy Birkin

Tel: +44 (0)121 265 6330

Investor relations and UK media
ICIS
Tom Moriarty / Caroline Evans Jones

Tel: +44 (0)20 7651 8688

US media relations
Adam Dubitsky

Tel: +1 202-652-2250

About Imaginatik

Imaginatik is the leading provider of innovation and collaborative problem solving software and process to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit <http://www.imaginatik.com>